Literature DB >> 15701764

Impact of topiramate on serum bicarbonate concentrations in adults.

Shauna S Garris1, Karen S Oles.   

Abstract

BACKGROUND: Topiramate is an antiepileptic medication with multiple pharmacologic effects, including inhibition of carbonic anhydrase activity. It is associated with metabolic acidosis in both children and adults.
OBJECTIVE: To evaluate the incidence and magnitude of the effect of topiramate on serum bicarbonate concentrations in an adult population.
METHODS: This was a retrospective cohort study. Data were evaluated to assess the relationship between serum bicarbonate concentrations before and during topiramate therapy.
RESULTS: Fifty-four patients (40 females) with a mean age of 47.6 years (range 19-89) were included in the study. Mean +/- SD serum bicarbonate concentrations before and during topiramate therapy were 26.8 +/- 2.9 mEq/L (range 21-36) and 21.7 +/- 3.6 mEq/L (range 13-29), respectively, with a mean difference of 5.1 (95% CI 3.7 to 6.5; p < 0.001). Twenty-six patients (48%) had low serum bicarbonate concentrations while on topiramate, with a mean concentration of 18.8 mEq/L (range 13-21).
CONCLUSIONS: Topiramate was associated with metabolic acidosis in 48% of the patients studied, which did not result in clinically significant problems.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701764     DOI: 10.1345/aph.1E437

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  12 in total

1.  American Society of Nephrology quiz and questionnaire 2014: acid-base and electrolyte disorders.

Authors:  Mitchell H Rosner; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-23       Impact factor: 8.237

Review 2.  Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.

Authors:  Martin J Brodie
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

Review 3.  Pharmacologically-induced metabolic acidosis: a review.

Authors:  George Liamis; Haralampos J Milionis; Moses Elisaf
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

4.  Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy.

Authors:  Elahna Paul; Kerry D Conant; Irie E Dunne; Heidi H Pfeifer; David A Lyczkowski; Michael A Linshaw; Elizabeth A Thiele
Journal:  Epilepsy Res       Date:  2010-05-13       Impact factor: 3.045

Review 5.  Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review.

Authors:  Valentina G Dell'Orto; Eva A Belotti; Barbara Goeggel-Simonetti; Giacomo D Simonetti; Gian Paolo Ramelli; Mario G Bianchetti; Sebastiano A G Lava
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

Review 6.  Topiramate: a review of its use in the treatment of epilepsy.

Authors:  Katherine A Lyseng-Williamson; Lily P H Yang
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate.

Authors:  Richard P Shank; Bruce E Maryanoff
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 8.  Spotlight on topiramate in epilepsy.

Authors:  Katherine A Lyseng-Williamson; Lily P H Yang
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  Effect of topiramate on acid-base balance: extent, mechanism and effects.

Authors:  Nasir Mirza; Anthony G Marson; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2009-11       Impact factor: 4.335

10.  Topiramate in the treatment of partial and generalized epilepsy.

Authors:  Edward Faught
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.